Nasdaq
$13.66▲ 2.02%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.21BShares out 88.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 8.7Regular26.08.07 23:59SCHEDULE 13GOwnership#●●●#●●●
Syndax Pharmaceuticals Inc
State Street Corp가 Syndax Pharmaceuticals Inc의 주식에 대해 5% 이상의 지분을 보유한 대량보유자로서 Schedule 13G 공시를 제출하였습니다. 이는 기관 투자자의 지분 변동에 따른 의무 공시로, 해당 기업에 대한 기관의 투자 현황을 공식화한 것입니다.…more
$13.66+2.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.4After-hours26.08.05 05:0410-QEarnings
Syndax Pharmaceuticals Inc
신닥스 파마슈티컬스(SNDX)는 2026년 6월 30일 기준 분기 보고서(10-Q)를 통해 2026년 주식 인센티브 플랜(Equity Incentive Plan)을 도입하고 관련 스톡옵션 및 제한조건부주식(RSU) 부여 규정을 공시했습니다. 2026년 7월 31일 기준 발행 주식 수는 89,297,086주이며, 회사는 레부메닙(Revumenib) 및 악사틸리맙(Axatilimab) 등 주요 파이프라인의 연구개발과 상업화 전략을 지속하고 있습니다.…more
$13.66+2.02%vs prev closeView filingShare - 8.4After-hours26.08.05 05:028-KKey event
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals는 2026년 2분기 총 매출 7,280만 달러를 기록하며 전년 동기 대비 92% 성장했습니다. 주요 제품인 Revuforj는 5,470만 달러, Niktimvo는 1,810만 달러의 매출을 달성했으며, 회사는 현재 5억 7,510만 달러의 현금 및 투자 자산을 보유하여 수익성 달성을 위한 재무 기반을 확보했습니다.…more
$13.66+2.02%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15After-hours26.10.16 05:01#●●●#●●●
Syndax’s Revuforj Named to TIME’s Best Inventions of 2026 List
Syndax Pharmaceuticals announced that its leukemia treatment, Revuforj, was named one of TIME's Best Inventions of 2026. This recognition highlights the product's innovation but does not provide immediate material financial impact for investors.…more
$13.66+2.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.13Regular26.10.14 01:24
●●●●●●●● ●●●●● ●●●●●●
Syndax Pharmaceuticals announced the discontinuation of its clinical development for axatilimab in idiopathic pulmonary fibrosis after failing to meet primary endpoints in a Phase 2 trial. The company's stock price dropped significantly following the announcement of the unsuccessful study results.…more
$13.66+2.02%vs prev closeShareBenzinga - 10.12After-hours26.10.13 05:01
●●●●●●●● ●●●●● ●●●●●●
Syndax Pharmaceuticals announced that its Phase 2 trial for Axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. Consequently, the company has decided to discontinue the development of the drug for this specific indication.…more
$13.66+2.02%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report